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Abstract
Aims/hypothesis Traditional blood glucose lowering agents
do not prevent the progressive loss of beta cell function in
patients with type 2 diabetes. The dipeptidylpeptidase
(DPP)-4 inhibitor vildagliptin improves beta cell function
both acutely and chronically (up to 2 years). Whether this
effect persists after cessation of treatment remains unknown.
Here, we assessed the insulin secretory capacity in drug-naive
patients with type 2 diabetes after a 52 week treatment period
with vildagliptin or placebo, and again after a 12 week
washout period.
Methods This study was conducted at a single university
medical centre, and was a double-blind, randomised clinical
trial in 59 drug-naive patients with type 2 diabetes and mild
hyperglycaemia to either vildagliptin 100 mg (n=29) or
placebo (n=30). Randomisation was performed by a
validated 1:1 system. Neither patient, nor caregiver, was
informed about the assigned treatment. Inclusion criteria
were drug-naive patients ≥30 years, with HbA1c ≤7.5% and
BMI of 22–45 kg/m2. The mildly hyperglycaemic patient
population was chosen to minimise glucose toxicity as a
confounding variable. Beta-cell function was measured
during an arginine-stimulated hyperglycaemic clamp at
week 0, week 52 and after a 12 week washout period. All
patients with at least one post-randomisation measure were
analysed (intent-to-treat).
Results Fifty-two week vildagliptin 100 mg (n=26) treat-
ment increased the primary efficacy variable, combined
hyperglycaemia and arginine-stimulated C-peptide secre-
tion (AIRarg), by 5.0±1.8 nmol/l×min, while it decreased
by 0.8±1.8 nmol/l×min with placebo (n=25) (between-
group difference p=0.030). No significant between-group
difference in AIRarg was seen after the 12 week washout
period. The between-group difference adjusted mean
52 week changes from baseline was −0.19±0.11, p=0.098
and −0.22±0.23%, p=0.343 for HbA1c and fasting plasma
glucose, respectively. There were no suspected drug
treatment-related serious adverse events.
Conclusions/interpretation One year treatment with vilda-
gliptin significantly increased beta cell secretory capacity.
This effect was not maintained after the washout, indicating
that this increased capacity was not a disease modifying
effect on beta cell mass and/or function.
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Introduction
The relationship between the insulin secretion rate and
increasing glucose concentration is the most basic reflection
of beta cell function. This relationship includes components
of sensitivity and capacity [1] as outlined in Fig. 1.
The sensitivity of insulin secretion to glucose is an early
defect in beta cell function [2]. The capacity to secrete
insulin is thought to be related to beta cell mass, which is
determined by the balance of the rate of beta cell
neogenesis and apoptosis. Insulin secretory capacity [2]
and beta cell mass [3, 4] are known to be reduced in
patients with type 2 diabetes. Glucagon-like peptide (GLP)-
1 increases beta cell mass via increased beta cell neogenesis
and decreased beta cell apoptosis in animal models [5] and
the levels of GLP-1 required for these effects are in the
range seen with dipeptidylpeptidase (DPP)-4 inhibitors [6].
The DPP-4 inhibitor vildagliptin has been shown to
increase beta cell function in humans as a result of improved
sensitivity of beta cells to glucose [7]. Furthermore, after
12 weeks of vildagliptin treatment, a small increase in the
capacity for insulin secretion has been shown [8]. The
present study was designed to test the hypothesis that this
capacity would increase further after 1 year of vildagliptin
treatment and that, if the increased capacity was due to a
disease modifying effect on beta cell mass, it would still be
present after a 3 month washout.
Methods
Subjects and study design This was a single centre, double-
blind, randomised, parallel-group study that was designed
to investigate the mechanisms by which vildagliptin
improves beta cell function. The study was not designed
to investigate the therapeutic potential of vildagliptin on
glycaemic efficacy in patients with type 2 diabetes. In total,
59 drug-naive patients with type 2 diabetes and mild
hyperglycaemiawere randomly assigned to receive vildagliptin
100 mg once daily or placebo (1:1 ratio). No treatment with
oral glucose lowering agents for at least 12 weeks prior
to study entry, or for >3 consecutive months at any time
in the past, was allowed.
The mildly hyperglycaemic patient population was
chosen to minimise glucose toxicity as a confounding
variable. All patients received lifestyle counselling. Inclu-
sion criteria were age ≥30 years, HbA1c ≤7.5%, and BMI of
22–45 kg/m2. The study protocol was approved by the
ethics review committee and was in accordance with the
principles described in the declaration of Helsinki. All
participating patients gave their written informed consent
before screening.
Study endpoints Insulin secretion and sensitivity were
measured during a combined euglycaemic–hyperinsulinaemic
and hyperglycaemic clamp procedure, as previously described
[9]. First and second phase C-peptide secretion were
calculated as the incremental (i)AUC180-190min and
iAUC240-260min. Arginine-stimulated C-peptide secretion
(AIRarg) was calculated as the iAUC260–270min. All
incremental AUCs were calculated above the C-peptide
concentration just prior to the start of the hyperglycaemic
clamp procedure (average of 170 and 175 min). Arginine
was administered during the hyperglycaemic clamp to
measure insulin secretory capacity at a steady-state
glucose concentration of 15 mmol/l. Clamps were
performed prior to randomisation, following 52 weeks
of treatment, and after a 12 week off-drug period
(week 64). Following an overnight fast, an indwelling
cannula was inserted into an antecubital vein for infusion
of glucose and insulin. To obtain arterialised venous
blood samples, an indwelling cannula was inserted in a
retrograde fashion into a dorsal hand or wrist vein and
Fig. 1 Relationship between the insulin secretion rate and increasing
glucose concentration
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maintained in a heated box at 50°C. During the clamp at
week 52, patients received their study medication at the
protocol specified time, i.e. 15 min prior to the start of
the euglycaemic–hyperinsulinaemic and hyperglycaemic
clamp procedure.
HbA1c (using a DCCT standardised HA 8160 analyser,
Menarini, Florence, Italy; normal range: 4.3–6.1%), fasting
plasma glucose (FPG), and safety variables were measured
prior to randomisation and during each follow-up visit until
the end of the 12 week off-drug period, by a central
laboratory (Covance, Geneva, Switzerland). Plasma glucose
concentrations during the clamp were measured at the
bedside using a YSI 2300 STAT Plus (Yellow Springs
Instruments, Yellow Springs, OH, USA). C-peptide samples
were analysed at the VU University Medical Centre using an
immunoradiometric assay (Centaur;Bayer Diagnostics,
Mijdrecht, the Netherlands).
Statistical analysis A sample size of 30 patients per group
was required to provide 90% power to detect a
significant between-group difference in AIRarg. All
patients randomised with at least one post-randomisation
measure were analysed, i.e. intent-to-treat. All outcome
measures are compared between the two treatment groups
using an analysis of covariance (ANCOVA) model. The
dependent variable used in the model is the change from
pre-treatment for the beta cell function variables (AIRarg,
first phase, second phase). For all other endpoints the
dependent value used is the mean at the corresponding
visit. The model included a factor for treatment group
(vildagliptin/placebo), and the pre-treatment variable of the
corresponding dependent variable as a covariate. Statistical
analysis was done using SAS software (SAS Institute, Cary,
NC, USA). All inferential statistical tests were conducted at a
significance level of 0.05 (two sided). Data are presented as
mean±SEM.
Results
Patient disposition and pre-treatment clinical characteristics
Patient disposition and pre-treatment clinical character-
istics are depicted in Fig. 2 and Table 1, respectively.
Ninety patients entered the screening phase of our study,
during which 17 did not meet the inclusion criteria. Of
the patients found eligible to participate in the current
study, 11 patients were excluded because of failure to
agree to participate after screening in a potential placebo
arm or in the clamp, or because of the investigators’
opinion that the participant could not meet the demands
of this 15 month study, which included three hyper-
insulinaemic–euglycaemic and hyperglycaemic clamps. Fi-
nally, three patients withdrew their consent prior to
randomisation. In the vildagliptin group, 29 patients were
randomised and 27 patients completed the study; one patient
withdrew consent because of an unsatisfactory therapeutic
effect and another was excluded because of a protocol
violation. In the placebo group 30 patients were randomised
and 27 patients completed the study; two patients discon-
tinued because of an adverse effect; a third withdrew consent.
Baseline clinical characteristics of the randomised population
were comparable in both treatment groups: mean age 57.4±
9.4 years vs 57.0±6.7 years, 58.6% vs 60.0% male, 96.6% vs
90.0% Europid, BMI 29.9±4.9 kg/m2 vs 29.2±4.4 kg/m2,
HbA1c 6.0±0.7% vs 6.0±0.7%, FPG 7.0±1.2 mmol/l vs
7.1±1.0 mmol/l and duration of diabetes 1.4±2.8 years
vs 0.6±1.1 years, for vildagliptin and placebo groups,
respectively.
Haemoglobin A1c and fasting plasma glucose Figure 3a,b
depicts the HbA1c and FPG concentrations during the
duration of the study. After 52 weeks of treatment, in the
vildagliptin group the mean change from baseline in HbA1c
(6.0±0.7%) was −0.1% and in FPG (7.0±1.2 mmol/l)
was −0.1 mmol/l, and in the placebo group the mean
change from baseline in HbA1c (6.0±0.7%) was +0.1% and
in FPG (7.1±1.0 mmol/l) was +0.1 mmol/l (Fig. 2a,b),
resulting in a non-significant between-group difference
of −0.19±0.11, p=0.098 and −0.22±0.23%, p=0.343 for
HbA1c and FPG, respectively.
Insulin sensitivity and hyperglycaemic clamp derived
measures of beta cell function Prior to randomisation, no
between-group differences were present in beta cell
function measures (Table 2). One year treatment with
vildagliptin significantly increased arginine-stimulated
C-peptide secretion during hyperglycaemia, the primary
endpoint of the study, compared with placebo (adjusted
mean±SEM change from pre-treatment: +5.0±1.8 nmol/l×
min and −0.8±1.8 nmol/l×min respectively; between-group
adjusted mean±SEM difference: 5.8±2.6 nmol/l×min
p=0.030) (Fig. 3c,e). First and sustained phase glucose
stimulated C-peptide secretion also improved after 1 year of
vildagliptin treatment (between-group adjusted mean±SEM
difference: +0.77±0.38, p=0.047 and +9.89±3.19,
p=0.003, respectively). In our study no statistically signif-
icant effect on insulin sensitivity, measured using the
euglycaemic–hyperinsulinaemic clamp, was observed.
Treatment-induced change in M value was +0.77±
1.9 mg kg−1 min−1 and +0.55±1.72 mg kg−1 min−1, for
vildagliptin and placebo, respectively.
Vildagliptin increased the disposition index (AIRarg×M
value) after 52 weeks of treatment by 49.6±15.0 nmol×
mg l−1 kg−1 (Fig. 3f). However, the placebo-adjusted mean
change from pre-treatment in the disposition index (AIRarg×
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M value) 32.0 nmol×mg l−1 kg−1 did not reach statistical
significance (p=0.142). The above-mentioned effects were
not sustained following the 12 week washout period; no
statistically significant difference between the two groups
was observed at week 64 (p=0.791; Fig. 3d–f).
Adverse effects and tolerability Vildagliptin treatment was
generally well-tolerated. Adverse events occurred at
similar rates across treatment groups (89.7% in the
vildagliptin group, 90.0% in the placebo group). Large
or consistent differences between active treatments and
the corresponding placebo groups for these types of
adverse events were not observed. The most frequently
observed adverse events were common infections such as
nasopharyngitis and bronchitis. Most adverse events were
isolated and occurred in just one patient in any treatment
group, and no clustering of any specific event was noted.
Two serious adverse events were observed during the
study in the vildagliptin group (nephrolithiasis and prostate
cancer); these events were not believed to be due to drug
treatment and did not result in discontinuation from the study.
One serious adverse event occurred in the placebo group
(hyperkalaemia); this event led to discontinuation from the
study.
Table 1 Demographics and baseline characteristics
Variable Vildagliptin 100 mg
once daily
Placebo
n 29 30
Age (years) 57.4±9.4 57.0±6.7
Men 17 (58.6) 18 (60.0)
Europid 28 (96.6) 27 (90.0)
Body weight (kg) 90.2±15.9 87.6±19.1
BMI (kg/m2) 29.9±4.9 29.2±4.4
Waist circumference (cm) 100.7±10.9 99.5±12.8
HbA1c (%) 6.0±0.7 6.0±0.7
FPG (mmol/l) 7.0±1.2 7.1±1.0
Disease duration (y) 1.4±2.8 0.6±1.1
Data are presented as mean±SD or n (%)
Assessed for eligibility (n=90)
Excluded 
- Did not meet inclusion criteria (n=17) 
- Investigator decision (n=11) 
- Withdrew consent (n=3) 
Randomised (n=59) 
 
Allocated to placebo (n=30) 
 
- Received allocated intervention (n=30) 
Completed until week 52 (n=27) 
 
Discontinued intervention (n=3) 
- Adverse event (n=2) 
- Withdrew consent (n=1) 
 
Completed until week 52 (n=27) 
 
Discontinued between weeks 52 and 64 (n=0)
 
Allocated to vildagliptin 100 mg daily (n=29)
- Received allocated intervention (n=29)
Completed until week 52 (n=28) 
 
Discontinued intervention (n=1) 
- Withdrew consent (n=1)
Completed until week 64 (n=27) 
 
Discontinued between weeks 52 and 64 (n=1) 
- Loss of glycaemic control (n=1) 
Fig. 2 Protocol flow-chart and
patient disposition
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Discussion
The combined glucose and arginine-stimulated C-peptide
secretion rate is the established measure of beta cell
capacity to secrete insulin [2, 9]. In the current study, 1 year
treatment with vildagliptin 100 mg once daily significantly
increased beta cell capacity to secrete insulin as reflected by
a ~15% increase relative to placebo in the combined
glucose and arginine-stimulated C-peptide secretion rate.
By design this was measured after an overnight fast; thus,
any increased meal-related acute stimulation of insulin
secretion due to increased GLP-1 and glucose-dependent
insulinotropic peptide (GIP) was not obscuring any poten-
tial increase in insulin secretion capacity. The glucose
toxicity associated with increasing FPG is known to reduce
beta cell function and any agent that reduces FPG is
predicted to improve beta cell function [10]. In order to
avoid this confounding variable, the design of the current
study attempted to minimise glucose toxicity. The lack of
important differences in glycaemic control as measured by
either FPG or HbA1c, or of a significant effect on insulin
resistance, indicates that glucose toxicity was in fact
minimised in the study. It was also planned that the
capacity would be corrected for any residual insulin
resistance by calculating the disposition index (AIRarg×M
value). The mean between-group difference in the disposi-
tion index tended to increase to a similar degree to the
difference seen with AIRarg,, but unlike AIRarg this
difference was not significant. Presumably any discrimina-
tion between the treatment groups arising from this ratio
appears to be offset by the increased variation. A previous
study with 50 mg vildagliptin twice daily [8] demonstrated
that after 3 months there was a ~9% increase in the capacity
for insulin secretion. A 9% increase after 3 months in the
previous study and a 15% increase after 12 months in the
current study suggests, but does not provide adequate
evidence, that the beta cell capacity is increasing over time.
In any case, if beta cell capacity is increasing it is doing so
Fig. 3 HbA1c (a) and fasting
plasma glucose (b) profiles
during the treatment period;
C-peptide concentrations during
hyperglycaemic clamp at
week 52, on-drug (c) and
week 64, off-drug (d); change
from pre-treatment in combined
hyperglycaemic and arginine-
stimulated C-peptide secretion
(e), and disposition index (f),
in the vildagliptin and placebo
treated group. Data represent
mean (SEM) in a–d and
adjusted LS mean (SEM) in e–f.
AIRarg, C-peptide response to
arginine at 15 mmol/l glucose
concentration; DI, disposition
index. See the Methods section
for calculations of beta cell
function measures. Black circles
and black bars, vildagliptin
100 mg daily; white circles and
white bars, placebo
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at a very slow rate. The 0.2% decrease in HbA1c from a
baseline of 6.0% in the current study is consistent with
previous vildagliptin (50 mg daily) studies where there was a
0.15% decrease from a baseline of 5.9% in a study with
participants with IGT [11] and a 0.3% decrease from a
baseline of 6.7% in a study with patients with type 2 diabetes
[12]. Although the changes in HbA1c in these previous IGT
and diabetes studies were not large, the increase in beta cell
function following treatment was much greater than that seen
in the current study. Both of these previous studies measured
overall beta cell function during meals and in the diabetes
study it was determined that increase was due to an
improvement in the sensitivity of insulin secretion to glucose
[12]. In contrast, in the current study, as indicated above, by
design any meal-related stimulation of insulin secretion due
to increased GLP-1 and GIP was not obscuring any potential
increase in insulin secretion capacity. Thus in the present
study, the beta cell capacity component (after an overnight
fast) of the improved insulin secretion seen with vildagliptin
treatment is small relative to the glucose-sensing component
observed during meals.
Twelve weeks of washout was chosen to test whether
any increase in capacity was due to a disease modifying
effect. This length of time was chosen so as eliminate any
post-dosing effects of vildagliptin to maintain higher GLP-1
and GIP levels as well as any reversible effects due to an
improved metabolic state. It was assumed that any increase
in beta cell mass would not be reversible within a 3 month
period of time. The ~15% effect on beta cell capacity in the
current study was not maintained after a 3 month washout
period, indicating that this increased beta cell capacity after
1 year of vildagliptin treatment was not a disease modifying
effect on beta cell functional mass. This suggests that
vildagliptin increased beta cell capacity after 1 year by a
more reversible mechanism. It has recently been reported
that, following vildagliptin treatment for 12 days, insulin
secretion was increased during a morning intravenous
glucose challenge after an overnight fast [13]; the effects
on capacity seen in the current study could thus be due to
increased basal GLP-1 and GIP.
The data from the current study are consistent with a
previous 1 year study where the GLP-1 mimetic, exenatide,
was shown to significantly improve beta cell capacity,
which, however, returned to the pre-treatment values after a
4 week washout [9]. The two studies differ in that patients
had higher levels of hyperglycaemia in the exenatide study;
thus there was an important change from baseline in
glucose toxicity that was controlled for by equivalent
glycaemic control with insulin therapy in the control group.
Furthermore, the acute effect of exenatide to increase
insulin secretion above non-treated values is much greater
than that seen with vildagliptin after an overnight fast.
Interestingly, there was improved beta cell function
4 weeks after washout from 2 years vildagliptin treatment
[12] and after 3 years exenatide treatment [14]. However, in
these longer-term studies, the contribution of increased
capacity vs improved sensitivity of the beta cells to glucose,
to the overall effect on beta cell function, was not assessed.
It is entirely possible that, after several years of treatment, it
is the improved glucose sensing that is persisting after
4 weeks washout, and not the capacity. Whether longer
treatments with DPP-4 inhibitors or GLP-1 receptor
Table 2 Measures of beta cell secretory function during hyperglycaemic clamp and change from pre-treatment in the vildagliptin (n=29) and
placebo (n=30) groups
Measurements Pre-treatment
(week 0)
On-drug
(week 52)
Off-drug
(week 64)
On-drug change to
pre-treatment (week 52)
Off-drug change
to pre-treatment (week 64)
Adjusted LS
mean
Between-group
difference
p value Adjusted LS mean Between-group
difference
p value
1st phase
Placebo 2.95±0.58 2.92±0.52 4.14±0.89 −0.02±0.27 0.95±0.58
Vildagliptin 2.94±0.61 3.55±0.65 3.44±0.82 0.75±0.26 0.77±0.38 0.047 0.81±0.60 −0.14±0.84 0.870
2nd phase
Placebo 34.05±4.10 32.92±4.05 32.83±3.78 −1.07±2.21 −2.16±2.53
Vildagliptin 35.06±3.60 43.94±5.36 38.06±5.76 8.82±2.21 9.89±3.19 0.003 2.99±2.59 5.15±3.62 0.162
AIRarg
Placebo 39.05±4.56 38.29±4.65 38.24±4.59 −0.77±1.84 0.40±1.73
Vildagliptin 39.04±3.58 42.81±4.72 39.32±5.28 5.00±1.81 5.77±2.58 0.030 1.44±1.81 1.04±2.51 0.680
Data are presented as mean±SEM. Changes from pre-treatment are presented as adjusted LS mean±SEM
1st phase, first phase C-peptide response to glucose (nmol/l×min); 2nd phase, second phase C-peptide response to glucose (nmol/l×min); AIRarg,
C-peptide response to arginine at 15 mmol/l glucose concentration (nmol/l×min); See the Methods for calculations of beta cell function measures
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activators have disease modifying effects on beta cell mass
in humans remains to be determined.
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